Latest Breaking News On - அலோக் மாலிக் - Page 4 : comparemela.com

Glenmark Pharmaceuticals launches SUTIB 2021-02-15 22:34:37 (Time Zone: Arizona, USA) Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approx. 96% lower than the MRP compared to the innovator brand, priced at Rs. 7000 (50 mg), Rs. 3600 (25 mg) and Rs. 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA). Kidney cancer (renal cell carcinoma) is a disease of uncontrolled cell growth in the lining of small tubes in the kidney. In the past decade, advances in research and drug development have begun to shift the paradigm of this disease. Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell car

United statesAlok malikDrug administrationGroup viceGlenmark pharmaceuticalsTime zonePancreatic neuroendocrineGroup vice presidentBusiness headIndia formulationsஒன்றுபட்டது மாநிலங்களில்அலோக் மாலிக்குழு துணைக்ளேண்மர்க் மருந்துகள்நேரம் ஸோந்கணையம் நியூரோஎண்டோகிரைன்